Strides Pharma Science gets nod to raise Rs 150 crore via NCDs
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Strides Pharma Science’s board has approved the offering for subscription, on a private placement basis, up to 1,500 senior, secured, rated, unlisted, redeemable, non-convertible debentures (NCDs) of face value Rs 10 lakh each, aggregating up to Rs 150 crore. The board of directors, at its meeting, held on July 25, 2022 has considered and approved the same.
Strides Pharma Science (Formerly Strides Shasun) is a pharmaceutical company with a major focus on development and manufacture of IP-led niche finished dosage formulations. It is also among the world’s largest manufacturers of soft gelatin capsules.
.jpg)
